Le Lézard
Classified in: Health, Science and technology
Subject: ACC

Correction missing MAR reference: Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023


MÖLNDAL, Sweden, Nov. 10, 2023 /PRNewswire/ -- For technical and administrative reasons, the previous press release was missing the appropriate MAR reference which is now added. All other items remain the same. Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that it expects its revenue, operating profit and cash flow for Q2 will be higher than the market expectations.

The revenue for Q2 is expected to be at 27,5 MSEK (20,2), which corresponds to an increase of 36,2% in comparison to last year. The operating profit for Q2 is expected to be at 6,4 MSEK (0,9). Excluding direct currency effects, the operating profit is expected to be at 4,1 MSEK (-5,2). The increase in operating profit can be attributed to both the increase in activity but also an improved cost structure for operating costs.

The cash flow for the quarter is expected to be 3,4 MSEK (-3,8).

All amounts in this press release are preliminary and have not undergone any review by the company auditors.

The complete result for Integrum will be presented in the quarterly report for August - October 2023 which is published on December 4, 2023. This means that the company is still in its quiet period.

This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-11-2023 16:50 CET.

For more information please contact:

Rickard Brĺnemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: [email protected]

Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: [email protected]

Certified Adviser
Erik Penser Bank is Certified Adviser.

The following files are available for download:

https://mb.cision.com/Public/17531/3873887/93156e7cb6e90976.pdf

2023-11-10 Correction Integrum publishes Q2 results

 

SOURCE Integrum AB


These press releases may also interest you

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...



News published on and distributed by: